Stay updated with breaking news from Amy Wolf. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif* (bosutinib) at 96 weeks (37.6% vs. 15.8%), building on 24-week
68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with a remarkable safety profile1 Sustained clinical benefit from Kymriah
Investegate announcements from NOVARTIS AG CHF0.50(REGD), FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
Latest in HR+/HER2- metastatic breast cancer, including data on CDK recycling with Kisqali plus endocrine therapy, further MONALEESA-2 quality of life and overall survival analyses, and a new biomarker
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis data at ASCO and EHA showcase latest oncology research and innovation, including in breast and prostate cancer